Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.23 USD

38.23
1,385,282

-0.39 (-1.01%)

Updated Aug 8, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.

Zacks Equity Research

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

by Zacks Equity Research

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Zacks Equity Research

Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.

Zacks Equity Research

Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent

by Zacks Equity Research

Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Zacks Equity Research

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.

Zacks Equity Research

Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss

by Zacks Equity Research

Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.

Zacks Equity Research

AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance

by Zacks Equity Research

AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.

Zacks Equity Research

Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag

by Zacks Equity Research

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

Zacks Equity Research

Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

Zacks Equity Research

TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down

by Zacks Equity Research

TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.

Zacks Equity Research

Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings

by Zacks Equity Research

AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Zacks Equity Research

Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down

by Zacks Equity Research

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

Zacks Equity Research

What's in the Cards for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

by Kinjel Shah

J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.

Zacks Equity Research

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

Zacks Equity Research

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Zacks Equity Research

Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19

by Zacks Equity Research

Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Zacks Equity Research

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Zacks Equity Research

Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe

by Zacks Equity Research

Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.

Zacks Equity Research

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

Zacks Equity Research

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

by Zacks Equity Research

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study

by Zacks Equity Research

Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.

Zacks Equity Research

Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail

by Zacks Equity Research

Regeneron (REGN) announces encouraging data on antibody cocktail, REGEN-COV, from two phase III studies.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

by Zacks Equity Research

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

Zacks Equity Research

Novartis (NVS) Teams Up With Artios for Radioligand Therapies

by Zacks Equity Research

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.